{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:51:52Z","timestamp":1781589112137,"version":"3.54.5"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["451221"],"award-info":[{"award-number":["451221"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>In 2019, British Columbia (BC) became the first jurisdiction in North America to introduce a mandatory non\u2010medical switching (NMS) policy requiring patients with Crohn's disease (CD) and ulcerative colitis (UC) to be switched from originator biologics to biosimilar equivalents. This study examines the influence of the BC Biosimilars Initiative NMS policy on the longer\u2010term infliximab and adalimumab biosimilar utilization and patterns of continuation\/discontinuation of biosimilars.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used health administrative data from BC to study drug utilization trends between 2015 and 2022. We used an interrupted time series design with segmented regression analysis to evaluate the impact of the Biosimilars Initiative on the utilization of biosimilars for infliximab and adalimumab and marginal Cox regression models to explore predictors of discontinuation of biosimilars post NMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The Biosimilars Initiative was associated with an increase in the proportion of biosimilars within the anti\u2010TNF market of 29.3% (95% CI: 28.6%, 29.9%) in Phase 1 (infliximab) and 49.5% (95% CI: 48.4%, 50.7%) in the adalimumab phase; thereafter, biosimilar use increased by 1.5% per year (95% CI: 0.3%, 2.7%). After the NMS, by the end of 2022, 13.5% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094648) had switched from a biosimilar to an originator or a biologic in a different class. Female patients and biologic\u2010naive patients starting on a biosimilar were more likely to switch from a biosimilar to another drug.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest that the Biosimilars Initiative NMS in BC was successful in switching patients to biosimilars and that most patients remained on biosimilar versions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.70395","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:40:51Z","timestamp":1779252051000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Longer\u2010Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population\u2010Based Study"],"prefix":"10.1002","volume":"35","author":[{"given":"Mark","family":"Harrison","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences University of British Columbia  Vancouver British Columbia Canada"},{"name":"Centre for Advancing Health Outcomes St. Paul's Hospital  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Blitz","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes St. Paul's Hospital  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Law","sequence":"additional","affiliation":[{"name":"School of Population and Public Health University of British Columbia  Vancouver British Columbia Canada"},{"name":"Department of Community Health Sciences University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy University of Toronto  Toronto Ontario Canada"},{"name":"Women's College Research Institute Women's College Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1468-1965","authenticated-orcid":false,"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[{"name":"Women's College Research Institute Women's College Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Clement","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Faculty of Medicine University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslam","family":"Anis","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes St. Paul's Hospital  Vancouver British Columbia Canada"},{"name":"School of Population and Public Health University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Bansback","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes St. Paul's Hospital  Vancouver British Columbia Canada"},{"name":"School of Population and Public Health University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i12.3146"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S4512"},{"key":"e_1_2_10_4_1","unstructured":"Canada PMPRB \u201cBiosimilars in Canada: Policies to Promote Switching and What It Means for Payers [Internet] \u201d(2025) https:\/\/www.canada.ca\/en\/patented\u2010medicine\u2010prices\u2010review\/services\/npduis\/analytical\u2010studies\/slide\u2010presentations\/cahspr2025\u2010biosimilars.html."},{"key":"e_1_2_10_5_1","unstructured":"\u201cPrescribed Drug Spending in Canada 2023 | CIHI [Internet] \u201dhttps:\/\/www.cihi.ca\/en\/prescribed\u2010drug\u2010spending\u2010in\u2010canada\u20102023?utm_campaign=PDEX\u201011\u201002\u20102023&utm_content=PDEX&utm_medium=social\u2010organic&utm_term=PDEX23_EN&utm_source=chatgpt.com."},{"key":"e_1_2_10_6_1","volume-title":"CompassRx, 6th Edition: Annual Public Drug Plan Expenditure Report, 2018\/19 [Internet]","author":"Patented Medicine Prices Review Board","year":"2020"},{"key":"e_1_2_10_7_1","unstructured":"Patented Medicine Prices Review Board \u201cBiosimilars in Canada: Current Environment and Future Opportunity [Internet] \u201d(2019) http:\/\/pmprb\u2010cepmb.gc.ca."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11106"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.3188"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-025-00709-1"},{"key":"e_1_2_10_11_1","unstructured":"BC Ministry of Health \u201cB.C. Expands Use of Biosimilars to Offer Coverage for More Treatment Options [Internet] \u201d(2019) https:\/\/news.gov.bc.ca\/releases\/2019HLTH0080\u2010001072."},{"key":"e_1_2_10_12_1","unstructured":"BC Ministry of Health \u201cB.C. Expands Biosimilars Program [Internet] \u201d(2019) https:\/\/news.gov.bc.ca\/releases\/2019HLTH0125\u2010001718."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1618195"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2024.927"},{"key":"e_1_2_10_15_1","unstructured":"Business in Vancouver Pacific Blue Cross \u201cHealthy Decision on Biosimilar Drugs Creates Big Savings for B.C. Employer Benefit Plans [Internet] \u201d(2019) https:\/\/biv.com\/article\/2019\/11\/healthy\u2010decision\u2010biosimilar\u2010drugs\u2010creates\u2010big\u2010savings\u2010bc\u2010employer\u2010benefit\u2010plans."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)30068\u20105"},{"key":"e_1_2_10_17_1","volume-title":"Switching From Innovator to Biosimilar (Subsequent Entry) Infliximab: An Updated Review of the Clinical Effectiveness, Cost\u2010Effectiveness, and Guidelines","year":"2017"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwz044"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S285610"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2037846"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwz035"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/2794220"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i46.4904"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwae011"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.23889\/ijpds.v4i2.1133"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009735"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/278495"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.02.019"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-015-7983-4_14"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25099"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.211478"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231201728"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251378080"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010021\u201000508\u20104"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70395","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:56:28Z","timestamp":1781585788000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/pds.70395"],"URL":"https:\/\/doi.org\/10.1002\/pds.70395","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"2025-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70395"}}